The University of Chicago Header Logo

Connection

Rohan Katipally to Ipilimumab

Back to Details
This is a "connection" page, showing publications Rohan Katipally has written about Ipilimumab.
Rohan Katipally
Connection Strength
0.052
Ipilimumab
  1. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.